Scienture LLC

Scienture is focused on bridging gaps in patient treatment delivery systems to improve healthcare outcomes.

We work for a healthier world where the burden of disease is lightened through accessible, affordable, tailored therapies.

Press Releases

We discover and deliver selectively designed drug innovations that enhance the treatment experience. It all starts with the patient.

Press Releases

Moving beyond traditional therapies, we aim to improve adherence journeys for patients whose needs have been overlooked.

Press Releases

SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Learn More

Press Releases

SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet

Learn More

Press Releases

SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions

Learn More

Press Releases

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Learn More

Press Releases

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

Learn More

Press Releases

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Learn More

See all

We invest in Delivering Better™

We are focused on identification and thoughtful selection of key access, commercialization, and support partners.

Press Releases

Prioritizing Patients.

Improving Outcomes.

Scienture is focused on bridging gaps in patient treatment delivery systems to improve healthcare outcomes.

Press Releases

Press Releases

Press Releases

Press Releases

Press Releases

Press Releases